Sio Gene Therapies Inc represents values of innovation, integrity, and patient-centricity. With a strong corporate philosophy focused on improving the lives of patients, Sio Gene Therapies Inc is dedicated to developing transformative gene therapies for various genetic and neurological disorders. Through cutting-edge scientific research and collaborative partnerships, the company aims to bring hope and effective treatments to those in need. Sio Gene Therapies Inc's commitment to delivering life-changing therapies aligns with its vision to redefine medical possibilities and provide a brighter future for patients worldwide.

Sio Gene Therapies Inc is primarily present in the United States.

Sio Gene Therapies Inc has achieved several significant milestones. Firstly, the company successfully completed a phase 1/2 clinical trial for AXO-Lenti-PD, a gene therapy candidate for Parkinson's disease. This breakthrough demonstrated the therapy's safety and potential efficacy. Additionally, Sio Gene Therapies received FDA Fast Track designation for AXO-AAV-GM1, a gene therapy for GM1 gangliosidosis, a rare neurodegenerative disorder. The company also entered a collaboration with Axovant Gene Therapies to develop and commercialize gene therapies for different CNS diseases. Moreover, Sio Gene Therapies received Orphan Drug Designation for AXO-AAV-GM2, a gene therapy targeting Tay-Sachs and Sandhoff diseases. These achievements highlight the company's dedication to revolutionizing the treatment of debilitating genetic diseases.

Sio Gene Therapies Inc, formerly known as Axovant Gene Therapies, is a biotechnology company focused on developing and commercializing gene therapies for neurological disorders. Founded in 2014, Sio Gene Therapies has its headquarters in New York City. The company aims to provide innovative treatments for various genetic and neurodegenerative diseases, including Parkinson's disease, Tay-Sachs disease, and ALS. With a commitment to advancing gene therapy research, Sio Gene Therapies collaborates with leading academic institutions and industry partners. By leveraging cutting-edge gene therapy technologies, the company strives to improve the lives of patients worldwide.

The main competitors of Sio Gene Therapies Inc in the market include companies such as Novartis AG, Pfizer Inc., and Spark Therapeutics Inc. These companies also specialize in the development and commercialization of gene therapies, making them direct competitors of Sio Gene Therapies Inc.

Sio Gene Therapies Inc is primarily active in the biotechnology and pharmaceutical industries. As a leading gene therapy company, Sio Gene Therapies Inc focuses on developing and delivering transformative genetic medicines for patients with neurological diseases. With their cutting-edge technology and innovative research, Sio Gene Therapies Inc is dedicated to addressing unmet medical needs and improving the lives of individuals affected by genetic disorders. By leveraging their expertise in gene therapy, Sio Gene Therapies Inc aims to revolutionize the treatment landscape and create long-lasting solutions for patients in need.

The business model of Sio Gene Therapies Inc is focused on developing and commercializing gene therapies to treat genetic and neurodegenerative diseases. Sio Gene Therapies aims to leverage its expertise in genetic medicine and gene delivery platforms to deliver transformative therapies. The company's approach involves using gene therapy to address underlying genetic causes, aiming for long-lasting and potentially curative treatments. By developing innovative gene therapies, Sio Gene Therapies aims to improve patient outcomes and address significant unmet medical needs in various therapeutic areas.

De Sio Gene Therapies K/W is -0,54.

De Sio Gene Therapies KUV is 2,15.

De AlleAktien Kwaliteitsscore voor Sio Gene Therapies is 1/10.

De verwachte Sio Gene Therapies omzet is 16,27 mln. USD.

De verwachte Sio Gene Therapies winst is -64,90 mln. USD.

Sio Gene Therapies is a biotechnology company focused on the development and commercialization of gene therapy products for rare and neurological diseases. The company is headquartered in New York and is listed on NASDAQ under the ticker symbol "SIOX". Sio Gene Therapies' business model is based on the discovery and development of novel gene therapies for the treatment of genetic diseases. The company has unique expertise in the development of adeno-associated virus (AAV)-based gene therapies and collaborates closely with leading scientists and academic institutions to develop new technologies and therapies. Sio Gene Therapies has a pipeline of therapeutics in various stages of clinical development. The company's products are designed to treat the genetic mutations that cause specific diseases. These gene therapies can directly repair the defective gene or introduce a healthy gene into the body to replace the faulty function of the corresponding protein. The different divisions of Sio Gene Therapies include the clinical development of gene therapies for rare diseases and neurological diseases. The company has a range of gene therapies in development aimed at treating diseases such as Huntington's disease, spinal muscular atrophy, Friedreich's ataxia, and Angelman syndrome. The flagship product of Sio Gene Therapies is AXO-Lenti-PD, a gene therapy for the treatment of Parkinson's disease. The company developed this therapy in collaboration with the College of Medicine at the University of Florida. It is a Phase 2 clinical trial aimed at alleviating the symptoms of Parkinson's in patients by directly repairing the Parkinson's-causing gene. Sio Gene Therapies has also entered into a strategic partnership with Asklepios BioPharmaceuticals, Inc. to expand access to AAV-based gene therapies. This joint venture aims to accelerate the clinical development and manufacturing of gene therapies and further enhance expertise in gene therapy development. Overall, Sio Gene Therapies' business model is based on the discovery and development of novel gene therapy products for the treatment of genetic diseases. The company focuses on the clinical development of gene therapies for rare and neurological diseases and has a range of products in various stages of clinical development. With AXO-Lenti-PD, the company has already achieved an important milestone in gene therapy development. Sio Gene Therapies is a biotechnology company specializing in the development and commercialization of gene therapy products for rare and neurological diseases. Its headquarters are in New York and it is listed on NASDAQ under the symbol "SIOX". The company's business model is centered around discovering and developing innovative gene therapies to treat genetic disorders. Sio Gene Therapies has expertise in developing adeno-associated virus (AAV)-based gene therapies and collaborates with leading scientists and academic institutions to create new technologies and therapies. The company has a pipeline of therapeutics in various stages of clinical development. These products aim to treat specific diseases by repairing defective genes or introducing healthy genes into the body to replace dysfunctional proteins. Sio Gene Therapies focuses on the clinical development of gene therapies for rare and neurological diseases and has several therapies in development for conditions such as Huntington's disease, spinal muscular atrophy, Friedreich's ataxia, and Angelman syndrome. Its flagship product, AXO-Lenti-PD, is a gene therapy for Parkinson's disease developed in collaboration with the College of Medicine at the University of Florida. This therapy is currently in Phase 2 clinical trials and aims to alleviate Parkinson's symptoms by directly repairing the disease-causing gene. Sio Gene Therapies has also formed a strategic partnership with Asklepios BioPharmaceuticals, Inc. to expand access to AAV-based gene therapies and enhance expertise in gene therapy development and manufacturing. In summary, Sio Gene Therapies' business model is based on discovering and developing innovative gene therapy products for genetic diseases. The company focuses on the clinical development of gene therapies for rare and neurological diseases and has achieved a significant milestone with AXO-Lenti-PD.

Sio Gene Therapies keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Sio Gene Therapies of het bedrijf keert geen dividend uit.

De ISIN van Sio Gene Therapies is US8293991043.

Het WKN van Sio Gene Therapies is A2QHKW.

De ticker van Sio Gene Therapies is SIOX.

Binnen de laatste 12 maanden betaalde Sio Gene Therapies een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Sio Gene Therapies naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Sio Gene Therapies is momenteel .

Sio Gene Therapies betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Sio Gene Therapies betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Sio Gene Therapies wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Sio Gene Therapies van 28-8-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 28-8-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 28-8-2024.

In het jaar 2023 heeft Sio Gene Therapies 0 USD aan dividenden uitgekeerd.

De dividenden van Sio Gene Therapies worden in USD uitgekeerd.